Profound Medical (NASDAQ:PROF) Releases Earnings Results, Beats Expectations By $0.05 EPS

Profound Medical (NASDAQ:PROF) issued its earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05, Zacks reports. The company had revenue of $5.34 million for the quarter, compared to analysts’ expectations of $4.85 million. Profound Medical had a negative net margin of 206.76% and a negative return on equity of 84.67%.

Here are the key takeaways from Profound Medical’s conference call:

• Q1 financials and outlook: Revenue was CAD 5.3M (up 104% YoY) with a 72% gross margin, operating expenses down 9%, net loss narrowed to CAD 7M, cash of CAD 50.3M, and management guiding to ~CAD 25M revenue and 70%+ gross margin for 2026 while reiterating a path to profitable growth.
• Strong clinical validation from CAPTAIN: The level?1 CAPTAIN trial showed TULSA delivered statistically superior quality?of?life and safety versus robotic prostatectomy (better urinary/erectile function preservation at 6 months) and complements a >70?paper evidence base demonstrating broad, durable efficacy.
• Commercial traction and reimbursement progress: Install base was 80 systems at quarter end (8 systems sold, 6 shipped but not yet installed), a triple?digit sales pipeline, new TULSA Index and patient?mix reporting (91% whole or >50% ablations), plus Humana coverage and private?payer reimbursements generally ~1.5–2.5x Medicare with ~80% success on appeals.
• Milestones and execution risks remain: Management expects FDA clearance for integration with new interventional MRI by year?end and targets 200 sites at 50 cases/year for profitability, but growth depends on MR availability, radiology/urology coordination, and the lag between system shipments and installations, so near?term guidance is deliberately conservative.

Profound Medical Stock Performance

Profound Medical stock traded down $0.31 during trading hours on Friday, hitting $6.85. The company had a trading volume of 189,347 shares, compared to its average volume of 94,559. The firm has a market cap of $248.93 million, a PE ratio of -5.52 and a beta of 0.73. The company has a debt-to-equity ratio of 0.07, a current ratio of 12.52 and a quick ratio of 11.17. Profound Medical has a one year low of $3.76 and a one year high of $8.95. The firm has a 50-day moving average of $6.40 and a 200 day moving average of $6.76.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PROF. Goldman Sachs Group Inc. raised its holdings in Profound Medical by 56.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,727 shares of the company’s stock valued at $147,000 after acquiring an additional 6,787 shares during the period. Corsair Capital Management L.P. bought a new position in Profound Medical in the 4th quarter valued at about $208,000. Millennium Management LLC bought a new position in Profound Medical in the 4th quarter valued at about $211,000. Quadrature Capital Ltd bought a new position in Profound Medical in the 4th quarter valued at about $256,000. Finally, Hohimer Wealth Management LLC bought a new position in Profound Medical in the 4th quarter valued at about $394,000. 47.86% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Profound Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $12.00.

Profound Medical Company Profile

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.